文献速递核素与放射性配体治疗神经核医学

211例接受131I-MIBG治疗的IV期肺及胃肠胰MIBG阳性神经内分泌肿瘤患者的生存预测因素

Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.
PubMed 文献 · J Nucl Med · 2018-05-18

该回顾性分析纳入1991至2014年间接受131I-MIBG治疗的211例IV期肺及胃肠胰MIBG阳性神经内分泌肿瘤患者,中位生存期29个月。首次随访时的症状缓解、生化缓解或稳定、影像缓解或稳定以及多轮131I-MIBG治疗均与生存获益相关,提示这些随访指标有助于预后判断。

要点

  • 211例IV期肺及胃肠胰MIBG阳性神经内分泌肿瘤患者接受131I-MIBG治疗,中位生存期29个月。
  • 首次随访症状缓解者占71%,中位症状缓解持续12个月,与30个月生存获益相关(P < 0.001)。
  • 首次临床随访生化缓解占34%、实验室值稳定占48%,缓解或稳定较进展延长生存40个月(P < 0.03)。

核心结论

  • 治疗性131I-MIBG用于转移性肺及胃肠胰神经内分泌肿瘤似乎是一种有效的症状姑息手段。
  • 影像学、生化和症状随访有助于预测131I-MIBG治疗后的预期生存。
  • 多轮131I-MIBG治疗与生存延长相关。

研究设计与样本

  • 回顾性分析,纳入1991年至2014年间接受131I-MIBG治疗的211例MIBG阳性IV期肺及胃肠胰神经内分泌肿瘤患者。
  • 通过病历回顾提取生存、症状、影像和生化反应资料。
  • 125例有CT随访的患者中,76例影像可获取者按RECIST 1.1评估影像反应,49例影像无法回顾者依据放射科报告进行病历回顾评估。
  • 采用Kaplan-Meier分析和Cox多因素回归估计初始影像、生化反应和症状反应预测的生存与无进展生存获益。

主要发现

  • 所有患者治疗时均为IV期疾病,自治疗起中位生存期为29个月。
  • 71%的患者出现症状缓解,中位症状缓解持续时间为12个月。
  • 首次随访时的症状缓解预测30个月生存获益(P < 0.001)。
  • 首次临床随访时34%的患者出现生化缓解,48%的患者实验室值稳定;缓解或稳定较进展延长生存40个月(P < 0.03)。
  • 初始3个月随访影像中,20%的患者出现影像缓解、60%稳定,影像缓解或稳定延长生存32个月(P < 0.001);多次131I-MIBG治疗与额外24个月生存相关(P < 0.05)。

临床怎么用

  • 原文结论认为治疗性131I-MIBG用于转移性肺及胃肠胰神经内分泌肿瘤似乎是一种有效的症状姑息手段。
  • 原文结论认为影像学、生化和症状随访有助于预测131I-MIBG治疗后的预期生存。
  • 原文结论认为多轮131I-MIBG治疗与生存延长相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)-positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131I-MIBG between 1991 and 2014. For patients with CT follow-up (n = 125), imaging response was assessed by RECIST 1.1 if images were available (n = 76) or by chart review of the radiology report if images could not be reviewed (n = 49). Kaplan-Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo (P < 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo (P < 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo (P < 0.001). Additionally, multiple 131I-MIBG treatments were associated with 24 mo of additional survival (P < 0.05). Conclusion: Therapeutic 131I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131I-MIBG therapy. Multiple rounds of 131I-MIBG are associated with prolonged survival.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kane A, Thorpe MP, Morse MA, et al. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG. J Nucl Med. 2018. PMID: 29777005. doi:10.2967/jnumed.117.202150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。